News

The study will investigate the effects of once-daily closed triple combination therapy fluticasone furoate/ umeclidinium/vilanterol compared to therapy with the once-daily dual combination therapy, Relvar/Breo(R) (FF/VI). Comprising three

COMPASS is a randomized, double-blind, placebo-controlled, 26-week Phase 3 study evaluating volanesorsen in 113 patients with severe hypertriglyceridemia. The average incoming triglyceride level of patients in the study

Tresiba, first approved by the FDA in September 2015, is now indicated to improve glycemic control in patients with type 1 and type 2 diabetes from the age

Nimenrix is now the first and only MenACWY conjugate vaccine in the European Union (EU) that can be administered from six weeks of age with no upper age

The companies signed an exclusive option, collaboration and license agreement for the worldwide development and commercialization of Conatus’ emricasan, an investigational oral, pan-caspase inhibitor intended to treat non-alcoholic

Initial disease areas of focus will include Amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple other neurodegenerative disorders. Evotec has built an industrialised iPSC infrastructure that represents

The removal of the boxed warning is based on the outcomes of EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study), the largest smoking cessation clinical trial

This acquisition would add a once-daily oral H4 receptor antagonist in development for atopic dermatitis (AD), commonly known as eczema, to complement the growing Novartis dermatology portfolio and

The recommendation is for treating NSCLC patients whose tumors have high PD-L1 expression without any EGFR or ALK positive tumor mutations. The CHMP’s positive opinion came through from